Axsome TherapeuticsAXSM +1.83%52 Gross Margin % is 92.30% as of Mar. 2026, which is 2% above its 10-year median of 90.87. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 737 Biotechnology companies, Axsome Therapeutics ranks better than 89.15% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Axsome Therapeutics had a gross margin of 92.30% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Axsome Therapeutics Gross Margin % Related Terms
Axsome Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXSM vs IONS, EXEL, MDGL: Gross Margin % Comparison
For the Biotechnology subindustry, Axsome Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Axsome Therapeutics (AXSM) has a Gross Margin % of 92.30% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Axsome Therapeutics and its competitors. This is near median its historical median of 90.87. Over the past decade, Axsome Therapeutics' Gross Margin % has ranged from 89.61 to 92.60. According to the industry distribution chart, Axsome Therapeutics ranks #80 out of 737 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Axsome Therapeutics' Gross Margin % too high?
Axsome Therapeutics' current Gross Margin % of 92.30% is near median its 10-year median of 90.87. Over the past 10 years, this metric has ranged from a low of 89.61 to a high of 92.60. The Biotechnology industry median Gross Margin % is 60.92. Axsome Therapeutics' value of 92.30% is 51.5% above this industry median. Based on the distribution chart, Axsome Therapeutics ranks #80 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Gross Margin % compare to IONS and EXEL?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #80 out of 737 companies for Gross Margin %. This places Axsome Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Axsome Therapeutics' value of 92.30% is 51.5% above this benchmark. Historically, Axsome Therapeutics' own Gross Margin % has ranged from 89.61 to 92.60 over the past decade. While the company's 10-year median is 90.87 vs. the industry median of 60.92, Axsome Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axsome Therapeutics's current Gross Margin % of 92.30% is 51.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Axsome Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current Gross Margin % is 92.30%, which is near median its own 10-year median of 90.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current Gross Margin % is 92.30%, which is near median its 10-year median of 90.87 and 51.5% above the Biotechnology industry median of 60.92. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Gross Margin % is 92.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41.
GuruFocus considers Axsome Therapeutics to be Fairly Valued.
Key valuation signals for AXSM:
Gross Margin %: 92.30% (near median its 10-year median of 90.87)
GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
Industry Position: 51.5% above the Biotechnology median (#80 of 737)
No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for AXSM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXSM has been successfully added to your 
